1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Baseline demographics and clinical characteristics for all patients, split by progression status at 5 years^a
Sustained Disease Progression (n = 90) Stable Disease (n = 90) P Value
Female (No.) (%) 68 (75.6) 73 (81.1) .4
Age (yr) (mean) (SD) (median) 31.9 (7.9) 31.5 29.5 (7.8) 28.5 .04
Disease duration (yr) (mean) (SD) (median) 6.0 (5.8) 4.0 4.0 (4.3) 3.0 .01
EDSS (mean) (SD) 2.0 (1.0) 1.8 (0.8) .2
Median (range) 2.0 (0–3.5) 2.0 (0–3.5) 
Treatment assignment (No.) (%) 
    IFN-β 1a monotherapy 25 (27.8%) 34 (37.8%) .3
    IFN-β 1a + AZA 32 (35.6%) 26 (28.9%) 
    IFN-β 1a + AZA + Steroids 33 (36.7%) 30 (33.3%) 
Treatment switch^b 
Did not switch 34 (38%) 62 (69%) <.0001
Switched 56 (62%) 26 (29%) 
Note:—IFN-β indicates interferon-β; AZA, azathioprine.
↵a The difference of the means between the groups was calculated using the Student t test, Pearson χ² test, or Mann-Whitney rank sum test, as appropriate.
↵b Treatment switch was defined on the basis of a derived yes/no variable as to whether patients changed treatment status during the 5-year follow-up.